



ADMINISTRATIVE POLICY STATEMENT

Michigan Medicaid

Policy Name & Number	Date Effective
Pharmacogenomics-CYP Gene Testing-MI MCD-AD-1394	10/01/2023-01/31/2025
Policy Type	
ADMINISTRATIVE	

Administrative Policy Statement prepared by CareSource and its affiliates are derived from literature based on and supported by clinical guidelines, nationally recognized utilization and technology assessment guidelines, other medical management industry standards, and published MCO clinical policy guidelines. Medically necessary services include, but are not limited to, those health care services or supplies that are proper and necessary for the diagnosis or treatment of disease, illness, or injury and without which the patient can be expected to suffer prolonged, increased or new morbidity, impairment of function, dysfunction of a body organ or part, or significant pain and discomfort. These services meet the standards of good medical practice in the local area, are the lowest cost alternative, and are not provided mainly for the convenience of the member or provider. Medically necessary services also include those services defined in any Evidence of Coverage documents, Medical Policy Statements, Provider Manuals, Member Handbooks, and/or other policies and procedures.

Administrative Policy Statements prepared by CareSource and its affiliates do not ensure an authorization or payment of services. Please refer to the plan contract (often referred to as the Evidence of Coverage) for the service(s) referenced in the Administrative Policy Statement. If there is a conflict between the Administrative Policy Statement and the plan contract (i.e., Evidence of Coverage), then the plan contract (i.e., Evidence of Coverage) will be the controlling document used to make the determination.

According to the rules of Mental Health Parity Addiction Equity Act (MHPAEA), coverage for the diagnosis and treatment of a behavioral health disorder will not be subject to any limitations that are less favorable than the limitations that apply to medical conditions as covered under this policy.

Table of Contents

A. Subject.....	2
B. Background.....	2
C. Definitions	2
D. Policy	2
E. Conditions of Coverage.....	4
F. Related Policies/Rules.....	4
G. Review/Revision History.....	4
H. References.....	4

A. Subject

Pharmacogenomics-CYP Gene Testing

B. Background

Pharmacogenomics is an area of precision medicine that provides information about an individual's genes, influences therapeutic strategies, and assesses the likelihood of benefit or toxicity to a given drug. This form of medication management has been evaluated in a variety of clinical scenarios. As pharmacogenomics expands and laboratories offering testing proliferate, the value of a given test in terms of patient benefit may be obscured by multiple contributing factors, including exaggerated public marketing claims, inconsistencies in test standardization, continued patient variation in response to prescribed medication, incomplete knowledge of drug metabolism, and limitations in regulatory oversight. To manage these challenges, the clinical validity and clinical utility of a specific gene or biomarker with a specific drug target should demonstrate improvement in patient outcomes.

C. Definitions

- **Clinical Utility** - The likelihood that a test will, by prompting an intervention, result in an improved health outcome.
- **Clinical Validity** - The predictive value of a test for a given clinical outcome.
- **Unbundling** - HCPCS/CPT codes should be reported only if all services described by the code are performed. Multiple codes should not be reported if a single code exists that describes the services performed. The codes include all services usually performed as part of the procedure as a standard of medical/ surgical practice and should not be separately reported simply because codes exist for the services.

D. Policy

I. General Guidelines

- A. Biomarker testing with uncertain clinical significance in MCG will be considered experimental and investigational.
- B. Unbundling of codes in a panel is an incorrect billing practice and may result in payment recovery.
- C. Any drug, biologic, device, diagnostic, product, equipment, procedure, treatment, service, or supply used in or directly related to the diagnosis, evaluation, or treatment of a disease, injury, illness, or other health condition which CareSource determines in its sole discretion to be experimental or investigational is not covered by CareSource.

- II. Based on review of existing evidence, there are currently no clinical indications for the high-volume tests below, and the current role remains uncertain. Therefore, CareSource considers these requests experimental and investigational. This is not an all-inclusive list.

The ADMINISTRATIVE Policy Statement detailed above has received due consideration as defined in the ADMINISTRATIVE Policy Statement Policy and is approved.

CPT® Codes	Testing Examples
81225 - CYP2C19 (cytochrome P450, family 2, subfamily C, polypeptide 19) (e.g., drug metabolism), gene analysis, common variants (e.g., *2, *3, *4, *8, *17)	Genecept Assay, GeneSight, OneOme RightMed, PGxOnePlus, CQuentia, IDGenetix, PROOVE, GARSPREDX, SureGene, PharmacoDx
81226 - CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (e.g., drug metabolism), gene analysis, common variants (e.g., *2, *3, *4, *5, *6, *9, *10, *17, *19, *29, *35, *41, *1XN, *2XN, *4XN)	
81227 - CYP2C9 (cytochrome P450, family 2, subfamily C, polypeptide 9) (e.g., drug metabolism), gene analysis, common variants (e.g., *2, *3, *5, *6)	
81230 - CYP3A4 (cytochrome P450 family 3 subfamily A member 4) (e.g., drug metabolism), gene analysis, common variant(s) (e.g., *2, *22)	
81291 - MTHFR (5, 10-methylenetetrahydrofolate reductase) (e.g., hereditary hypercoagulability) gene analysis, common variants (e.g., 677T, 1298C)	
0345U – Psychiatry (e.g., depression, anxiety, attention deficit hyperactivity disorder [ADHD]), genomic analysis panel, variant analysis of 15 genes, including deletion/duplication analysis of CYP2D6	

III. CareSource applies coding edits to medical claims through coding logic software to evaluate the accuracy and adherence to accepted national standards. Proper billing and submission guidelines must be followed, including the following:

- A. Use of industry standard, compliant codes on all claims submissions, including Current Procedure Terminology (CPT) codes and/or Healthcare Common Procedure Coding System (HCPCS) codes.
- B. Services considered to be mutually exclusive, incidental to, or integral to the primary service rendered are not allowed additional payment.
- C. Proprietary panel testing requires evidence-based documentation of medical necessity.
- D. Submission of the most accurate and appropriate CPT/HCPCS code(s) for the product or service being provided, including coding to the highest level of specificity.

IV. CareSource considers the following not medically necessary (not an all-inclusive list):

- A. Pharmacogenomic testing or screening in the general population.
- B. A non-covered test billed using unlisted procedure codes.
- C. The use of multi-gene panels for genetic polymorphisms, including, but not limited to, pain management, cardiovascular drugs, anthracyclines, or polypharmacy, for evaluating drug-metabolizer status (ie, GeneSight ADHD, SureGene Test, PharmacoDx).
- D. Tests considered screening in the absence of clinical signs/symptoms of disease.
- E. Tests that do not confirm new data for decision making but confirm a known diagnosis or information.
- F. Tests to determine risk for developing a disease or condition.
- G. Tests without diagnosis-specific indications.
- H. Tests performed to ensure a tissue specimen matches an individual.

The ADMINISTRATIVE Policy Statement detailed above has received due consideration as defined in the ADMINISTRATIVE Policy Statement Policy and is approved.

E. Conditions of Coverage

Codes referenced in this policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage.

F. Related Policies/Rules

Overpayment Recovery
Experimental and Investigational Items and Services
Medical Necessity Determinations

G. Review/Revision History

	DATE	ACTION
Date Issued	09/27/2023	New policy. Approved at Committee.
Date Revised		
Date Effective	10/01/2023	
Date Archived	01/31/2025	This Policy is no longer active and has been archived. Please note that there could be other Policies that may have some of the same rules incorporated and CareSource reserves the right to follow CMS/State/NCCI guidelines without a formal documented Policy.

H. References

1. Attention-deficit hyperactivity disorder medication pharmacogenetics - ADRA2A, COMT, CYP2B6, and CYP2D6 genes: A-0764. MCG, 27th ed. Updated June 27, 2023. Accessed August 23, 2023. www.careweb.careguidelines.com
2. Centers for Disease Control and Prevention. *Clinical Laboratory Improvement Amendments (CLIA)*. US Dept of Health and Human Services; 2022. MLN-006270. Accessed August 23, 2023. www.cdc.gov
3. Clinical utility evaluation: APOE genetic testing for Alzheimer disease. Hayes Inc; 2018. Updated March 18, 2022. Accessed August 23, 2023. www.hayesinc.com
4. Clinical utility evaluation: MTHRF genetic testing for severe MTHFR enzyme deficiency. Hayes Inc; 2017. Updated May 23, 2021. Accessed August 23, 2023. www.hayesinc.com
5. Clinical utility evaluation: MTHRF genetic testing in common clinical conditions. Hayes Inc; 2017. Updated May 23, 2021. Accessed August 23, 2023. www.hayesinc.com
6. Clinical utility evaluation: MTHRF pharmacogenetic genotyping for altering drug treatment. Hayes Inc; 2017. Updated May 23, 2021. Accessed August 23, 2023. www.hayesinc.com
7. Clinical utility evaluation: pharmacogenetic and pharmacogenomic testing for opioid treatment for pain in adults-selected single gene variants and pharmacogenomic panels. Hayes Inc; 2019. Updated October 26, 2022. Accessed August 23, 2023. www.hayesinc.com
8. Clinical utility evaluation: pharmacogenetic and pharmacogenomic testing to improve outcomes related to opioid use disorder. Hayes Inc; 2020. Updated June 30, 2023. Accessed August 23, 2023. www.hayesinc.com

The ADMINISTRATIVE Policy Statement detailed above has received due consideration as defined in the ADMINISTRATIVE Policy Statement Policy and is approved.

9. Clinical utility evaluation: pharmacogenomic testing for attention-deficit/hyperactivity disorder. Hayes Inc; 2022. Updated March 30, 2023. Accessed August 23, 2023. www.hayesinc.com
10. Clinical utility evaluation: pharmacogenomic testing for opioid treatment for pain-OPRM1 and COMT variants. Hayes Inc; 2019. Updated October 24, 2022. Accessed August 23, 2023. www.hayesinc.com
11. Clinical utility evaluation: pharmacogenomic testing of selected mental health conditions. Hayes Inc; 2021. Accessed August 23, 2023. www.hayesinc.com
12. Clopidogrel pharmacogenetics - CYP2C19 gene: A-0631. MCG Health. 27th ed. Updated June 27, 2023. Accessed August 23, 2023. www.careweb.careguidelines.com
13. Deoxyribonucleic acid (DNA) fact sheet. National Human Genome Research Institute. Updated August 24, 2020. Accessed August 23, 2023. www.genome.gov
14. Empey P, Pratt VM, Hoffman J, et al. Expanding evidence leads to new pharmacogenomics payer coverage. *Genet Med*. 2021;23:830–832. doi.org/10.1038/s41436-021-01117-w
15. Hicks J, Bishop J, Sangkuhl K, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. *Clin Pharmacol Ther*. 2015;98(2):127-134. doi:10.1002/cpt.147
16. Hulick P. Next-generation DNA sequencing (NGS): principles and clinical applications. UpToDate. Updated August 10, 2022. Accessed August 23, 2023. www.uptodate.com
17. Kim S, Yun YM, Chae HJ, et al. Clinical pharmacogenetic testing and application: laboratory medicine clinical practice guidelines. *Ann Lab Med*. 2017;37(2):180-193. doi:10.3343/alm.2017.37.2.180
18. Kohlmann W, Slavotinek A. Genetic testing. UpToDate. Updated October 7, 2022. Accessed August 23, 2023. www.uptodate.com
19. Krishnan R. Unipolar depression: genetics. UpToDate. Updated October 26, 2022. Accessed August 23, 2023. www.uptodate.com
20. List of cleared or approved companion diagnostic devices (in vitro and imaging tools). Food and Drug Administration. Updated August 21, 2023. Accessed August 23, 2023. www.fda.gov
21. Molecular test assessment: Genesight psychotropic (Assurex Health Inc./Myriad Neuroscience). Hayes Inc; 2021. Updated October 20, 2022. Accessed August 23, 2023. www.hayesinc.com
22. Precision medicine research brief: Genecept Assay. Hayes Inc; 2016. Accessed August 23, 2023. www.hayesinc.com
23. Precision medicine research brief: PGxOne Plus (Admera Health). Hayes Inc; 2017. Accessed August 23, 2023. www.hayesinc.com
24. Precision medicine research brief: Proove Opioid Risk Test (Proove Biosciences). Hayes Inc; 2016. Accessed August 23, 2023. www.hayesinc.com
25. Medical code brief: 0345U-PLA (u codes). Hayes Inc; 2022. Archived August 14, 2023. Accessed August 23, 2023. www.hayesinc.com
26. Methotrexate pharmacogenetics - MTHFR gene: A-1009. MCG Health. 27th ed. Updated June 27, 2023. Accessed August 23, 2023.

The ADMINISTRATIVE Policy Statement detailed above has received due consideration as defined in the ADMINISTRATIVE Policy Statement Policy and is approved.

- www.careweb.careguidelines.com
27. *Michigan Medicaid Provider Manual*. Michigan Dept of Health and Human Services. Updated July 1, 2023. Accessed August 23, 2023. www.michigan.gov
 28. Naltrexone pharmacogenetics - OPRM1 gene: A-0845. MCG Health. 27th ed. Updated June 27, 2023. Accessed August 23, 2023. www.careweb.careguidelines.com
 29. *National Correct Coding Initiative Policy Manual For Medicaid Services*. Centers for Medicaid and Medicare Services; 2021. Accessed August 23, 2023. www.cdc.gov
 30. NCI dictionary of genetics terms. National Cancer Institute. Accessed August 23, 2023. www.cancer.gov
 31. Pharmacogenetic testing. American Academy of Child & Adolescent Psychiatry. Updated December, 2019. Accessed August 23, 2023. www.aacap.org
 32. Psychotropic medication pharmacogenetics - ABCB1, ADRA2A, BDNF, COMT, DRD, FKBP5, GNB3, HTR, MC4R, OGFRL1, SLC6A4, and TPH1 genes: A-0859. MCG Health. 27th ed. Updated June 27, 2023. Accessed August 23, 2023. www.careweb.careguidelines.com
 33. Psychotropic medication pharmacogenetics - CYP450 polymorphisms: A-0692. MCG Health. 27th ed. Updated June 27, 2023. Accessed August 23, 2023. www.careweb.careguidelines.com
 34. Psychotropic medication pharmacogenetics - gene panels: A-00861. MCG Health. 27th ed. Updated June 27, 2023. Accessed August 23, 2023. www.careweb.careguidelines.com
 35. Pharmacogenomics. National Institute of General Medical Sciences. Updated May 4, 2022. Accessed August 23, 2023. www.nigms.nih.gov
 36. Opioid pharmacogenetics - CYP450 polymorphisms and OPRM1 gene: A-0992. MCG Health. 27th ed. Updated June 27, 2023. Accessed August 23, 2023. www.careweb.careguidelines.com
 37. Raby B. Personalized medicine. UpToDate. Updated June 16, 2023. Accessed August 23, 2023. www.uptodate.com
 38. Tacrolimus pharmacogenetics - CYP3A4 and CYP3A5 genes: A-0775. MCG Health. 27th ed. Updated June 27, 2023. Accessed August 23, 2023. www.careweb.careguidelines.com
 39. Tamoxifen pharmacogenetics - CYP2D6 gene: A-0647. MCG Health. 27th ed. Updated June 27, 2023. Accessed August 23, 2023. www.careweb.careguidelines.com
 40. Tantisira K, Weiss S. Overview of pharmacogenomics. UpToDate. Updated June 14, 2023. Accessed August 23, 2023. www.uptodate.com
 41. Warfarin pharmacogenetics - CYP2C9, CYP4F2, and VKORC1 genes: A-0587. MCG Health. 27th ed. Updated June 27, 2023. Accessed August 23, 2023. www.careweb.careguidelines.com